Search results
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
In this article, we hear Colin's story and the reasons why he has hope for the future.
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
Wednesday 2 October, 11.00am - 1.00pm - In-person meet up at Visibility Scotland with guest speaker Graeme Marden from Sight and Sound Technology.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
Saturday 5 October, 10.00am - In-person - Come and join the Belfast Bumpers Group for a day out in Londonderry with lunch at The Exchange restaurant followed by a walk around The Derry Walls.
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
As part of our aim to nurture young scientists, we are very pleased to introduce one of our new PhD students as part of a co-funding agreement with the Macular Society.
My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called retinitis pigmentosa or RP for short, which will slowly lead to blindness.
Completing this form will enable Retina UK to claim tax back on eligible donations. It means that for every £1 you donate to Retina UK we can claim back 25p at no extra cost to you.
